Show simple item record

dc.contributor.authorEl-Saifi, N
dc.contributor.authorMoyle, W
dc.contributor.authorJones, C
dc.contributor.authorTuffaha, H
dc.date.accessioned2018-01-23T00:34:11Z
dc.date.available2018-01-23T00:34:11Z
dc.date.issued2016
dc.identifier.issn0269-4727
dc.identifier.doi10.1111/jcpt.12357
dc.identifier.urihttp://hdl.handle.net/10072/142344
dc.description.abstractWhat is known and objective Quetiapine is a second-generation antipsychotic that is commonly prescribed for a range of approved and off-label indications in older adults. However, little is known about its safety in this population. The available evidence on quetiapine safety is based on studies on second-generation antipsychotics as a group, often in the general population and for approved indications. There are no systematic reviews on the safety of quetiapine in older adults, and therefore, there is a need for systematically assessing quetiapine safety in this group of patients to establish an appropriate safety profile for this vulnerable population. The aim of this paper was to review and describe adverse drug events associated with quetiapine use in older adults. Methods A systematic literature search was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Databases searched were CINAHL, PubMed, Medline, PsycInfo and the Cochrane Library. Results and discussion Sixty-nine papers met the inclusion criteria. The majority of the studies (n = 36, 52%) were observational, and 11 (16%) were randomized controlled trials (RCTs). Most of the reported indications (75%) were off-label. The most commonly reported adverse events were somnolence (25–39%), dizziness (15–27%), headache (10–23%), postural hypotension (6–18%) and weight gain (11–30%). From the included RCTs, comparing quetiapine with placebo, quetiapine resulted in significantly greater cognitive impairment, higher rates of falls and injury and increased mortality in patients with parkinsonism, but not in patients with dementia. Compared with risperidone and olanzapine, quetiapine had significantly lower risk of mortality, reduced rate of cerebrovascular events, increased rate of falls and injury and less metabolic disorders compared with olanzapine, but higher metabolic disorders compared with risperidone. What is new and conclusion This work provides full characterization of quetiapine safety in older people, which may help healthcare providers better anticipate, prevent and manage ADEs in this population.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherWiley-Blackwell
dc.relation.ispartofpagefrom7
dc.relation.ispartofpageto18
dc.relation.ispartofissue1
dc.relation.ispartofjournalJournal of Clinical Pharmacy and Therapeutics
dc.relation.ispartofvolume41
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences not elsewhere classified
dc.subject.fieldofresearchcode3214
dc.subject.fieldofresearchcode321499
dc.titleQuetiapine safety in older adults: a systematic literature review
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, Menzies Health Institute
gro.hasfulltextNo Full Text
gro.griffith.authorMoyle, Wendy


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record